GAIT Authors Seek Further Study Of Moderate-To-Severe Arthritis Sufferers
This article was originally published in The Tan Sheet
Executive Summary
Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher
You may also be interested in...
Study Makes MOVES For Chondroitin/Glucosamine On Osteoarthritis Pain
At six months, 79.7% of the moderate-to-severe patients in the supplementation group and 79.2% in the celecoxib group fulfilled pain reduction criteria, the primary outcome measured in the Multicenter Osteoarthritis InterVEntion trial with SYSADOA.
Study Makes MOVES For Chondroitin/Glucosamine On Osteoarthritis Pain
At six months, 79.7% of the moderate-to-severe patients in the supplementation group and 79.2% in the celecoxib group fulfilled pain reduction criteria, the primary outcome measured in the Multicenter Osteoarthritis InterVEntion trial with SYSADOA.
GAIT II “Conflicts” With Existing Glucosamine/Chondroitin Data, CRN Says
Results of a follow-up glucosamine and chondroitin study measuring loss of knee cartilage in patients with osteoarthritis are inconsistent with the trial's earlier arm